Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/08/2859417/0/en/Mestag-Presents-Preclinical-Data-at-AACR-on-its-M300-Program-a-Conditionally-Active-LTBR-Agonist-Designed-to-Induce-Tertiary-Lymphoid-Structures-in-Tumors.html
https://www.globenewswire.com//news-release/2024/03/05/2840935/0/en/Mestag-Therapeutics-M300-Program-Designed-to-Conditionally-Induce-Tertiary-Lymphoid-Structures-in-Tumors-Selected-for-Late-Breaking-Poster-Presentation-at-AACR-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/02/28/2836925/0/en/Mestag-Therapeutics-to-Present-at-Evercore-ISI-2024-Emerging-Biotech-Conference.html
https://www.globenewswire.com//news-release/2024/02/20/2831806/0/en/Mestag-Therapeutics-Enlists-Leading-Cancer-Biology-and-Immunology-Advisors-to-Support-Clinical-Development-of-its-Lead-Oncology-Program.html